Misonix Reports Fourth Quarter and Fiscal Year 2009 Financi... (te500® which uses HIFU for the trea...)

Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results

Date:10/1/2009

te500®, which uses HIFU for the treatment of prostate cancer in Europe. We have expanded our sales force and added to our distribution network in Italy, Russia, Portugal, Romania, and Bulgaria.

As you know, we have been developing expertise in the exciting new area of High Intensity Focused Ultrasound ("HIFU"). To continue to be a leader in this field, we purchased HIFU related intellectual property that we believe will enable us to develop and manufacture new HIFU transducers. With the development of new transducers, we may be able to increase the type of tissue we can affect beyond our present rights in kidney, liver and breast.

We are continuing to complete clinical evaluation procedures using HIFU for the treatment of kidney tumors at the University of Vienna in Austria. We have received our second 510k in the United States for this treatment.

We are excited about the growth opportunities for our innovative ultrasonic medical device business. With a strengthened balance sheet, exciting new products, a new direct salesforce and broad based international distribution we believe that fiscal year 2010 will be one of growth and expansion for your Company."

Conference Call

Misonix management will host a conference call and webcast on Thursday, October 1, 2009 at 4:30 pm ET to discuss the Company's fourth quarter fiscal 2009 financial results.

The conference call will be broadcast live via the Investor Relations section of the Company's Web site at www.misonix.com. Alternatively, participants may join the conference call by dialing (866) 515-2909 (domestic) or (617) 399-5123 (international) and entering access code 61977194, a few minutes before the start of the call.

For those unable to attend the live results broadcasts, a recording of the live-call will be available approximately 2 hours after the event through October 8, 2009. The dial-i
'/>"/>

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors

Post Your Comments:

(Date:12/15/2009)... Dec. 15 ,, Reportlinker.com announces ... available in its catalogue: ,, Hepatitis ... Forecasts to 2015 ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ... Analysis and Market Forecasts to 2015 ,, ... analysis specialist,s new report, "Hepatitis B Vaccines ...

(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... A strategic assessment of the competitive ... highest priority management responsibilities, the task ... profitability. Timely and factual competitive intelligence ...

(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com ... report is available in its catalogue: ... Therapeutics - Market Forecasts to 2015, ... Analysis ,, http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... author has released its latest research ...

[0] Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 [0] Reportlinker Adds Top Ten World's Leading Orthopedics Companies [0] Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... to evaluate vandetanib as second-line NSCLC ... treatment in combination with docetaxel -, WILMINGTON, Del., Sept. ... show that the AstraZeneca,investigational once-daily oral anti-cancer drug vandetanib (ZACTIMA), ... advanced Non-Small Cell Lung Cancer (NSCLC). The Phase II ...

... to insulin glargine, exenatide offered added benefits of, ... used with metformin --, AMSTERDAM, Netherlands, Sept. ... and Eli Lilly and Company (NYSE: LLY ... injection,with insulin glargine on beta-cell function, glycemic control ...

Other Medicine Technology:Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 2 Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 3 Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 4 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 2 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 3 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 4 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 5 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 6 One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 7

Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. As competitors ... complete a product portfolio they also must face ... ,, A new free, white paper from Howard ... Conservation Program: US Airways ," details how the ... the newly formed company to enhance its occupational ...

(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com ... report is available in its catalogue: ... Diseases Therapeutics - Market Forecasts to ... Deals Analysis ,, http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... The author has released its latest ...

(Date:12/15/2009)... STAMFORD, Conn., Dec. 15 Aon ... of Aon Corporation (NYSE: AON ... the firm as senior vice president with ... of the national Pharmacy Practice. ,, ... her new role, Zeitel will work under ...

(Date:12/15/2009)... Research shows a direct correlation between effective workplace ... a culture of health improvement can result in ... new white paper from The Vitality Group, a ... an ideal setting for the delivery of health ... corporate culture of health is a critical component ...

(Date:12/15/2009)... -- Today, Coastal Healthcare Administrators officially announced ... the first time since its inception in ... will be assuming responsibilities and provider contracts ... Medical Care. ,, Operating on a ... working relationships with all network physicians, ancillary ...

[0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Aon Consulting Adds Senior Vice President to National Pharmacy Practice [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs [0] Coastal Healthcare Administrators Expands Provider Network to Santa Clara County

... raised about its autonomy, a high-level expert committee is confident ... "as immune as possible from authorities". ,"We hope ... AIIMS as immune as possible from authorities," M S Valiathan, ... committee on AIIMS affairs, told PTI from Manipal. ...

... associated with it begin at vessel branches and this ... which activate// a cellular protein that has been known ... link mechanical forces with structural and biochemical changes in ... form preferentially at branches of coronary arteries. ...

... a burning issue in Asian countries, especially with around ... ,Looking at the main causes of this condition, ... this growing condition is due to ignorance towards prevention ... found that the governments of some developing countries failed ...

... have time to attend support groups or can't afford the ... support for these mothers may be just a phone call ... Carolina College of Nursing researcher shows that regular phone calls ... are isolated because of their child’s illness and overwhelmed by ...

... Minster Anbumani Ramadoss has been pilloried back home for his ... of Medical Sciences (AIIMS), his// ministry has been honoured for ... ,The American Cancer Society has hailed India's Ministry of Health ... may aspire" and given it the award for Exemplary Leadership ...

... Recent research has revealed that gene mutations that are ... of Rett syndrome (RTT) in females are not always ... previous assumptions, and can occur sporadically in infant males ... published in the journal Neurology reports four sporadic occurrences ...

Other Medicine News:Health News:Atherosclerosis and its Mechanics 2 Health News:Atherosclerosis and its Mechanics 3 Health News:The Fight Against Hepatitis 2 Health News:Phone Calls Lend Vital Support to Moms of Mentally Ill Children 2 Health News:Phone Calls Lend Vital Support to Moms of Mentally Ill Children 3 Health News:Health Minister Ramadoss Honoured for his Exemplary Work 2 Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 2 Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 3

Expert panel confident of making AIIMS fully autonomous Atherosclerosis and its Mechanics The Fight Against Hepatitis Phone Calls Lend Vital Support to Moms of Mentally Ill Children Health Minister Ramadoss Honoured for his Exemplary Work Gene Mutations Causing Rett Syndrome Occur in Both Sexes

... Management software- RLISYS provides ... Software, Support, and Training ... Optometry, Ophthalmology, and Opticianry- ... operations, allowing you to ...

... The Advia 120 ... to streamline laboratory workflow ... benefits. This analyzer offers ... diagnostic assays, meeting the ...

The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis....

The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...

Medicine Products:

RLISYS Advia 120 K-4500 XT-1800i

Misonix Reports Fourth Quarter and Fiscal Year 2009 Financi...(te500® which uses HIFU for the trea...),Health